Alkermes Trial Suggests Orexin Drugs May Improve ADHD Symptoms

By Elaine Chen · STAT News · 2026-09-21

STAT News reports that the pharmaceutical firm Alkermes has successfully completed a Phase 1 trial for a new therapy targeting attention deficit hyperactivity disorder. The experimental drug, known as ALKS 7290, achieved a notable reduction in symptom severity among adult partici

STAT News reports that the pharmaceutical firm Alkermes has successfully completed a Phase 1 trial for a new therapy targeting attention deficit hyperactivity disorder. The experimental drug, known as ALKS 7290, achieved a notable reduction in symptom severity among adult partici